U.S. market Closed. Opens in 11 hours 52 minutes

ZVRA | Zevra Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue27.46M10.46M28.65M13.29M12.84MN/A
Cost of Revenue3.95M343.00K2.06M1.30M2.94MN/A
Gross Profit23.51M10.12M26.59M11.98M9.89MN/A
Operating Expenses73.11M34.96M18.86M16.76M30.23M54.27M
Selling, General & Admin34.31M15.34M8.70M7.92M10.82M12.51M
Research & Development38.80M19.61M10.16M8.84M19.41M41.76M
Other Operating ExpensesN/AN/AN/AN/AN/AN/A
Operating Income-49.60M-24.84M7.73M-4.78M-20.34M-55.90M
Other Expenses / Income3.56M-17.49M-16.25M-8.01M-4.21M4.34M
Before Tax Income-46.05M-42.33M-8.52M-12.79M-24.54M-56.59M
Income Tax ExpensesN/A-786.00K34.00K-34.00K-22.00K-126.00K
Net Income-46.05M-41.54M-8.55M-12.76M-24.52M-56.47M
Interest Expenses1.50M335.00K376.00K7.09M6.51M7.09M
Basic Shares Outstanding35.45M34.49M29.77M3.98M1.85M1.12M
Diluted Shares Outstanding35.45M34.49M29.77M3.98M1.85M1.12M
EBITDA-48.60M-24.08M7.98M-4.69M-20.03M-53.52M
EBITDA Margin-176.97%-230.27%27.84%-35.31%-155.99%0.00%
EBIT-44.55M-41.99M-8.14M-5.70M-18.03M-49.51M
EBIT Margin-162.22%-401.55%-28.43%-42.93%-140.43%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙